Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.67 |
| ▸ | EGFR | P00533 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23046214 | 1.00 | PTPN11 (0.67) | PTPN11KCNH2EGFR | |
| SCHEMBL30041490 | 1.00 | PTPN11 (0.67) | PTPN11KCNH2EGFR | |
| SCHEMBL21383804 | 1.00 | PTPN11 (0.67) | PTPN11KCNH2EGFR | |
| SCHEMBL30529690 | 1.00 | PTPN11 (0.67) | PTPN11KCNH2EGFR | |
| Hydrochloric Acid SCHEMBL23024430 | 0.99 | PTPN11 (0.66) | PTPN11KCNH2EGFR | |
| SCHEMBL22789726 | 0.94 | PTPN11 (0.58) | PTPN11KCNH2EGFR | |
| SCHEMBL22789665 | 0.93 | PTPN11 (0.58) | PTPN11KCNH2EGFR | |
| SCHEMBL24282605 | 0.91 | PTPN11 (0.64) | PTPN11KCNH2EGFR | |
| SCHEMBL22789653 | 0.91 | PTPN11 (0.64) | PTPN11KCNH2EGFR | |
| SCHEMBL22789585 | 0.91 | PTPN11 (0.55) | PTPN11KCNH2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4506035-A2 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12209074-B2 | SHP2 phosphatase allosteric inhibitor | BEIJING SHENOGEN PHARMA GROUP LTD. (CN) | 2025-01-28 | — | — | US | disclosed |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-3768668-B1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | D. E. SHAW RESEARCH, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | D. E. SHAW RESEARCH, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | D. E. SHAW RESEARCH, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20220388977-A1 | SHP2 PHOSPHATASE ALLOSTERIC INHIBITOR | BEIJING SHENOGEN PHARMA GROUP LTD. (CN) | 2022-12-08 | — | — | US | disclosed |
| US-20220388977-A1 | SHP2 PHOSPHATASE ALLOSTERIC INHIBITOR | BEIJING SHENOGEN PHARMA GROUP LTD. (CN) | 2022-12-08 | — | — | US | disclosed |
| EP-3984999-A1 | SHP2 PHOSPHATASE ALLOSTERIC INHIBITOR | Beijing Shenogen Pharma Group Ltd. (CN) | 2022-04-20 | — | — | EP | disclosed |
| EP-3984999-A1 | SHP2 PHOSPHATASE ALLOSTERIC INHIBITOR | Beijing Shenogen Pharma Group Ltd. (CN) | 2022-04-20 | — | — | EP | disclosed |
| US-20210393623-A1 | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2021-12-23 | — | — | US | disclosed |
| US-20210355105-A1 | REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2021-11-18 | — | — | US | disclosed |
| US-20210355105-A1 | REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2021-11-18 | — | — | US | disclosed |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| WO-2020249079-A1 | SHP2 PHOSPHATASE ALLOSTERIC INHIBITOR | 北京盛诺基医药科技股份有限公司 | 2020-12-17 | — | — | WO | disclosed |
| WO-2020249079-A1 | SHP2 PHOSPHATASE ALLOSTERIC INHIBITOR | 北京盛诺基医药科技股份有限公司 | 2020-12-17 | — | — | WO | disclosed |
| WO-2020063760-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355105-A1 | REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | PTPN11, PTPN1, PTPN7 | PTPN11 1/4885KCNH2 4613/4885EGFR 1050/4885 |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | PTPN11 14/4885KCNH2 4635/4885EGFR 793/4885 |
| US-20220388977-A1 | SHP2 PHOSPHATASE ALLOSTERIC INHIBITOR | PTPN1, PTPN5, PTPN18 | PTPN11 10/4885KCNH2 3331/4885EGFR 738/4885 |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | PTPN11 14/4885KCNH2 4635/4885EGFR 793/4885 |
| US-20210393623-A1 | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors | PTPN1, PTPN5, PTPN2 | PTPN11 10/4885KCNH2 4388/4885EGFR 629/4885 |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPRJ, PTPRC | PTPN11 20/4885KCNH2 4731/4885EGFR 973/4885 |
| US-12209074-B2 | SHP2 phosphatase allosteric inhibitor | PTPN1, PTPN5, PTPN18 | PTPN11 10/4885KCNH2 3331/4885EGFR 738/4885 |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | PTPN11 14/4885KCNH2 4635/4885EGFR 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.